Evaluation of the WATCHMAN left atrial appendage closure device

被引：8

作者：

Alli, Oluseun ^{[1
,2
]}

Holmes, David, Jr. ^{[3
,4
]}

机构：

[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA

[3] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA

[4] Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA

来源：

EXPERT REVIEW OF MEDICAL DEVICES | 2014年 / 11卷 / 06期

关键词：

atrial fibrillation; left atrial appendage; left atrial appendage occlusion; oral anticoagulant; PROTECT AF; WATCHMAN; STROKE PREVENTION; WARFARIN THERAPY; ANTITHROMBOTIC THERAPY; PERCUTANEOUS CLOSURE; RISK STRATIFICATION; EMBOLIC PROTECTION; PREDICTING STROKE; FIBRILLATION; ANTICOAGULATION; ASPIRIN;

D O I：

10.1586/17434440.2014.940315

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Left atrial appendage device occlusion for the preventions of systemic thromboembolism and stroke represents a major breakthrough in the field of cardiovascular disease. The wide prevalence of atrial fibrillation with devastating consequences of thromboembolic stroke as a result of thrombus arising from the left atrial appendage has led to the development of transcatheter and surgical based occlusion devices. Though this device is yet to be formally approved for a clinical indication in the USA, the WATCHMAN appendage occlusion device remains the most rigorously examined and studied of all transcatheter-based devices in this space. This review will focus on the needs assessment in this space, the technology of the current WATCHMAN device, trials and studies looking at safety and efficacy, specific patient populations who might benefit as well as future perspectives.

引用

页码：541 / 551

页数：11

共 43 条

[1] Quality of Life Assessment in the Randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Trial of Patients at Risk for Stroke With Nonvalvular Atrial Fibrillation [J].

Alli, Oluseun ;

Doshi, Shepal ;

Kar, Saibal ;

Reddy, Vivek ;

Sievert, Horst ;

Mullin, Chris ;

Swarup, Vijay ;

Whisenant, Brian ;

Holmes, David, Jr. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (17) :1790-1798

[2] Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients [J].

Apostolakis, Stavros ;

Lane, Deirdre A. ;

Guo, Yutao ;

Buller, Harry ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (03) :386-387

[3] Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation Initial Clinical Experience [J].

Bartus, Krzysztof ;

Han, Frederick T. ;

Bednarek, Jacek ;

Myc, Jacek ;

Kapelak, Boguslaw ;

Sadowski, Jerzy ;

Lelakowski, Jacek ;

Bartus, Stanislaw ;

Yakubov, Steven J. ;

Lee, Randall J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (02) :108-118

[4] Safety and Biocompatibility of the Coherex WaveCrest™ Left Atrial Appendage Occluder in a 30-Day Canine Study [J].

Cheng, Yanping ;

McGregor, Jenn ;

Sommer, Robert ;

Gray, William ;

Edmiston, Daryl ;

Conditt, Gerard ;

Yi, Genghua ;

Tellez, Armando ;

Rousselle, Serge ;

Granada, Juan ;

Kaluza, Greg .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) :B222-B223

[5] Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].

Connolly, S. ;

Pogue, J. ;

Hart, R. ;

Pfeffer, M. ;

Hohnloser, S. ;

Chrolavicius, S. ;

Yusuf, S. .

LANCET, 2006, 367 (9526) :1903-1912

[6] Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].

Connolly, S. J. ;

Yusuf, S. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. ;

Flather, M. ;

Hart, R. G. ;

Hohnloser, S. H. ;

Joyner, C. ;

Pfeffer, M. ;

Gaudin, C. ;

Blumenthal, M. ;

Marchese, C. ;

Pogue, J. ;

Hart, R. ;

Hohnloser, S. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Budaj, A. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Dorian, P. ;

Flaker, G. ;

Fox, K. A. A. ;

Franzosi, M. G. ;

Goldhaber, S. ;

Golitsyn, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Kozan, O. ;

Lanas, F. ;

Lau, P. ;

Le Heuzey, J. Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipilis, A. ;

Sitkei, E. ;

Swedberg, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078

[7] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[8] The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy [J].

Coppens, Michiel ;

Eikelboom, John W. ;

Hart, Robert G. ;

Yusuf, Salim ;

Lip, Gregory Y. H. ;

Dorian, Paul ;

Shestakovska, Olga ;

Connolly, Stuart J. .

EUROPEAN HEART JOURNAL, 2013, 34 (03) :170-176

[9]

Crandall MA, 2009, MAYO CLIN PROC, V84, P643, DOI 10.1016/S0025-6196(11)60754-4

[10]

Diener Hans-Christoph, 2007, Rev Neurol Dis, V4, P177

← 1 2 3 4 5 →